Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.
Also called NCT01823185
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,500 participants
- Sponsor
- Imam Abdulrahman Bin Faisal University
- Registry
-
NCT01823185
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Saudi Arabia
- Registry status
- Unknown status
Technical summary
Registry record NCT01823185. Non-randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
- Condition
- Coronary Artery Disease
- Condition
- Myocardial Infarction
- Condition
- Heart Disease
- Condition
- Vascular Disease
- Condition
- Angina Pectoris
- Condition
- Cardiovascular Disease
- Condition
- Ischemia
- Condition
- Infarction
- Condition
- Embolism
- Condition
- Thrombosis
- Condition
- Chest Pain
- Intervention (Drug)
- clopidogrel
- Intervention (Drug)
- Ticagrelor or prasugrel
- Lead sponsor
- Imam Abdulrahman Bin Faisal University
- Collaborator
- King Fahad Armed Forces Hospital
- Collaborator
- Dammam Central Hospital
Record details
- Record id
cardio:ct-nct01823185- Content hash
6b70e21660de8bcc7b8b29dc265271a5b3092938b9ad78e389a7bfbdc167cf83